Belgium's Solvay said it should have more clarity on the future of its pharmaceuticals unit in the fourth quarter. All options, including keeping the unit as-is, are still on the table, CEO Christian Jourquin said. Report
Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes
Wednesday, March 24 | 2pm ET / 11am PT
Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.